The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation†
Abstract
Orthotopic liver transplantation (OLT) can be a definitive treatment for patients with hepatocellular carcinoma (HCC). Prolonged waiting times for cadaveric livers, however, may lead to dropout from the waiting list or worsened post-OLT prognosis as a result of interval tumor progression. Percutaneous radiofrequency ablation (RFA) is widely used for local control of small unresectable HCC, but its pretransplant role remains unclear. We studied the outcome of 52 consecutive patients accepted for OLT bearing 87 HCC nodules and treated with percutaneous RFA. On initial staging, the tumor burden exceeded the Milan criteria in 10 patients. Complete tumor coagulation was observed in 74 of 87 (85.1%) nodules based on postablation imaging. After a mean of 12.7 months (range: 0.3-43.5) on the waiting list, 3 of 52 patients (5.8%) had dropped out due to tumor progression. Forty-one patients had undergone transplantation, with 1- and 3-year post-OLT survival rates of 85% and 76%, respectively. No patient developed HCC recurrence. There were three major complications in 76 RFA procedures (hepatic arterial hemorrhage, small bowel perforation, and liver decompensation salvaged by OLT), without resultant death or dropout. In conclusion, percutaneous RFA is an effective bridge to OLT for patients with compensated liver function and safely accessible tumors. Tumor-related dropout rate and post-OLT outcome compared favorably with published controls of patients with early-stage disease. This can be attributed to the efficacy of RFA in producing local cure or curbing tumor progression during the waiting period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., Ascher, N. L., & Roberts, J. P. (2001) · Hepatology · doi:10.1053/jhep.2001.24563 · Cited by 2,262
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
Livraghi, T., Solbiati, L., Meloni, M. F., Gazelle, G. S., Halpern, E. F., & Goldberg, S. N. (2003) · Radiology · doi:10.1148/radiol.2262012198 · Cited by 1,298
Small Hepatocellular Carcinoma: Treatment with Radio-frequency Ablation versus Ethanol Injection
Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni, F., Solbiati, L., & Gazelle, G. S. (1999) · Radiology · doi:10.1148/radiology.210.3.r99fe40655 · Cited by 1,283
Poon, R. T.-P., Fan, S. T., Lo, C. M., Liu, C. L., & Wong, J. (2002) · Annals of Surgery · doi:10.1097/00000658-200203000-00009 · Cited by 844
Radiofrequency Ablation of Hepatocellular Cancer in 110 Patients With Cirrhosis
Curley, S. A., Izzo, F., Ellis, L. M., Nicolas Vauthey, J., & Vallone, P. (2000) · Annals of Surgery · doi:10.1097/00000658-200009000-00010 · Cited by 731
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
Llovet, J. M., Fuster, J., & Bruix, J. (2004) · Liver Transplantation · doi:10.1002/lt.20034 · Cited by 700
Mazzaferro, V., Battiston, C., Perrone, S., Pulvirenti, A., Regalia, E., Romito, R., Sarli, D., Schiavo, M., Garbagnati, F., Marchianò, A., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000143301.56154.95 · Cited by 491
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“The main studies assessing neo-adjuvant treatments are case series, case–control studies and cohort studies showing that RFA achieves the higher rates of complete necrosis (12–55%) [224,225] compared with TACE (22–29%) [226–228].”
BackgroundPompili, M., Saviano, A., de Matthaeis, N., Cucchetti, A., Ardito, F., Federico, B., Brunello, F., Pinna, A. D., Giorgio, A., Giulini, S. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.009 · Cited by 285
Current epidemiology in hepatocellular carcinoma
Konyn, P., Ahmed, A., & Kim, D. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991792 · Cited by 280
Metadata
- Authors
- Lu, D. S. K., Yu, N. C., Raman, S. S., Lassman, C., Tong, M. J., Britten, C., Durazo, F., Saab, S., Han, S., Finn, R., Hiatt, J. R., & Busuttil, R. W.
- Venue
- Hepatology
- Published
- 2005-05
- Volume
- 41
- Issue
- 5
- Pages
- 1130-1137
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2130978854
- Cited by
- 355
- References
- 24
- FWCI
- 17.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation†. https://app.cochat.ai/papers/10.1002/hep.20688
- The paper
- Lu, D. S. K., Yu, N. C., Raman, S. S., Lassman, C., Tong, M. J., Britten, C., Durazo, F., Saab, S., Han, S., Finn, R., Hiatt, J. R., & Busuttil, R. W. (2005). Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation†. Hepatology. https://doi.org/10.1002/hep.20688
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
